Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cardiac disease - Larnax

Drug Profile

Research programme: cardiac disease - Larnax

Alternative Names: Cardiac disease research programme - Larnax

Latest Information Update: 20 Jul 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Larnax (CEASED)
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 31 Dec 2003 Discontinued - Preclinical for Cardiovascular disorders in Germany (unspecified route)
  • 01 Apr 2003 MediGene's cardiac and metabolic disease programme has been spun off as a new company, Larnax GmbH
  • 21 Oct 2002 MediGene and Evotec OAI, as GENOVATION, have entered into an agreement to codevelop this programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top